CALIFORNIA NANOTECHNOLOGIES (CNO.CA) Stock Fundamental Analysis
Canada - TSX-V:CNO - CA1304921010 - Common Stock
0.35 CAD
+0.01 (+2.94%)
CNO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 23 industry peers in the Machinery industry. While CNO seems to be doing ok healthwise, there are quite some concerns on its profitability. CNO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CNO had negative earnings in the past year.
CNO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CNO reported negative net income in multiple years.
In the past 5 years CNO always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -21.51%, CNO is doing worse than 69.57% of the companies in the same industry.
Looking at the Return On Equity, with a value of -39.65%, CNO is in line with its industry, outperforming 43.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROIC | N/A |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of CNO has grown nicely.
CNO's Gross Margin of 69.19% is amongst the best of the industry. CNO outperforms 100.00% of its industry peers.
In the last couple of years the Gross Margin of CNO has grown nicely.
The Profit Margin and Operating Margin are not available for CNO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% |
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
2. Health
2.1 Basic Checks
CNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CNO has more shares outstanding
The number of shares outstanding for CNO has been increased compared to 5 years ago.
The debt/assets ratio for CNO is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.70 indicates that CNO is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.70, CNO is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
CNO has a debt to FCF ratio of 4.46. This is a neutral value as CNO would need 4.46 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.46, CNO is in the better half of the industry, outperforming 73.91% of the companies in the same industry.
CNO has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.49, CNO perfoms like the industry average, outperforming 56.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Altman-Z | 2.7 |
ROIC/WACCN/A
WACC9.51%
2.3 Liquidity
CNO has a Current Ratio of 1.19. This is a normal value and indicates that CNO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.19, CNO is doing worse than 78.26% of the companies in the same industry.
A Quick Ratio of 1.19 indicates that CNO should not have too much problems paying its short term obligations.
CNO's Quick ratio of 1.19 is fine compared to the rest of the industry. CNO outperforms 73.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
CNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -477.78%.
Looking at the last year, CNO shows a very negative growth in Revenue. The Revenue has decreased by -17.79% in the last year.
Measured over the past years, CNO shows a very strong growth in Revenue. The Revenue has been growing by 49.59% on average per year.
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
3.2 Future
CNO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 102.46% yearly.
CNO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.08% yearly.
EPS Next Y100%
EPS Next 2Y102.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-42.17%
Revenue Next 2Y-11.08%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CNO. In the last year negative earnings were reported.
CNO is valuated rather expensively with a Price/Forward Earnings ratio of 24.24.
60.87% of the companies in the same industry are more expensive than CNO, based on the Price/Forward Earnings ratio.
CNO's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.24 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CNO.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CNO indicates a somewhat cheap valuation: CNO is cheaper than 73.91% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.49 | ||
| EV/EBITDA | 108.46 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CNO's earnings are expected to grow with 102.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y102.46%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CNO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:CNO (11/14/2025, 7:00:00 PM)
0.35
+0.01 (+2.94%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14.5%
Ins Owner ChangeN/A
Market Cap16.83M
Revenue(TTM)4.45M
Net Income(TTM)-939.70K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.24 | ||
| P/S | 2.7 | ||
| P/FCF | 36.49 | ||
| P/OCF | 5.75 | ||
| P/B | 5.06 | ||
| P/tB | 5.07 | ||
| EV/EBITDA | 108.46 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY4.13%
FCF(TTM)0.01
FCFY2.74%
OCF(TTM)0.06
OCFY17.39%
SpS0.13
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% | ||
| FCFM | 7.39% |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)19.86%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Debt/EBITDA | 9.55 | ||
| Cap/Depr | 253.96% | ||
| Cap/Sales | 39.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1711.31% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.7 |
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)145.85%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
EPS Next Y100%
EPS Next 2Y102.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
Revenue Next Year-42.17%
Revenue Next 2Y-11.08%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.85%
EBIT growth 3Y87.4%
EBIT growth 5Y154.28%
EBIT Next Year-68.11%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.62%
FCF growth 3Y80.29%
FCF growth 5Y42.36%
OCF growth 1Y667.86%
OCF growth 3Y173%
OCF growth 5Y84.63%
CALIFORNIA NANOTECHNOLOGIES / CNO.CA FAQ
What is the ChartMill fundamental rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CNO.CA.
Can you provide the valuation status for CALIFORNIA NANOTECHNOLOGIES?
ChartMill assigns a valuation rating of 4 / 10 to CALIFORNIA NANOTECHNOLOGIES (CNO.CA). This can be considered as Fairly Valued.
How profitable is CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
CALIFORNIA NANOTECHNOLOGIES (CNO.CA) has a profitability rating of 3 / 10.
What is the financial health of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
The financial health rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) is 4 / 10.